Developing molecular tools for cancer detection and COVID-19 testing
Clifton Life Sciences is a leader in the emerging field of liquid biopsies.
An innovative blood-based molecular signature platform
We combine our proprietary genomic profiles with our advanced informatics and data management software to provide an end-to end service.
Liquid Biopsy
We develop blood-based assays that function as liquid biopsies for solid tumours.
Diagnostics
Tumour RNA characteristics generate biological markers that can be used in medical testing.
Real-Time
Liquid biopsies provide real-time information about tumour pathobiology.
PCR & MAAA
Tumour RNA amplification protocols and multi-algorithmic analyses are performed.
Leaders in the emerging field of liquid biopsies
Clifton Life Sciences (CLS) is a leader in the emerging field of liquid biopsies. It focuses on the development of blood-based molecular diagnostic tests for personalized oncological medicine. The company’s products and services are based on its proprietary technology involving the identification of molecular signatures for a variety of different cancers.
Blood detection
CLS is developing novel molecular genomic blood detection systems for point-of-care diagnostic cancer applications including breast, colon, lung cancer, ovarian, pancreatic, prostate, melanoma, myeloma and neuroendocrine cancers.
CLS platform
The CLS platform integrates molecular gene cluster and defines cancer specific signatures. Genomic analysis produces high performance quantitative laboratory test results from venous or fingerprick blood samples.
Get in touch to discuss our Neuroendocrine and COVID-19 testing solutions.
